NewsAlkem Laboratories: Receives 7 Observations In US FDA Form 483 After Inspection Of Daman FacilityAlkem Laboratories: Receives 7 Observations In US FDA Form 483 After Inspection Of Daman Facility
Alkem Laboratories disclosed receiving Form 483 with seven observations after US FDA inspected its Daman manufacturing facility for 11 days. The company notified stock exchanges and committed to addressing all regulatory observations within stipulated timeframes, demonstrating compliance with pharmaceutical manufacturing standards.
*this image is generated using AI for illustrative purposes only.
Alkem Laboratories has notified stock exchanges about a recent US FDA inspection at its manufacturing facility located in Amaliya, Daman. The pharmaceutical company disclosed that the regulatory inspection resulted in Form 483 observations that require remedial action.
FDA Inspection Details
The US FDA conducted a comprehensive inspection of Alkem's Daman manufacturing facility over an 11-day period. The inspection timeline and outcomes are detailed below:
| Parameter: | Details |
|---|---|
| Inspection Period: | April 20, 2026 to May 1, 2026 |
| Facility Location: | Amaliya, Daman |
| Inspection Duration: | 11 days |
| Form 483 Observations: | 7 observations |
Regulatory Compliance Response
Following the completion of the FDA inspection, Alkem Laboratories received Form 483 containing seven specific observations. Form 483 is issued by the FDA to document conditions or practices that may constitute violations of the Food, Drug and Cosmetic Act and related regulations.
The company has formally committed to addressing all identified observations within the timeframe stipulated by regulatory requirements. This response demonstrates Alkem's commitment to maintaining compliance with international pharmaceutical manufacturing standards.
Corporate Communication
Alkem Laboratories communicated this development to both major Indian stock exchanges on May 2, 2026. The disclosure was made to BSE Limited and National Stock Exchange of India Limited as part of the company's regulatory reporting obligations. The communication was signed by Manish Narang, President-Legal, Company Secretary and Compliance Officer, ensuring proper corporate governance protocols were followed in the disclosure process.
Historical Stock Returns for Alkem Laboratories
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -0.73% | -2.90% | +1.16% | -2.98% | +4.78% | +94.29% |
Will the FDA observations impact Alkem's ability to supply products to the US market or delay pending drug approvals?
How might this FDA inspection outcome affect Alkem's stock performance and investor confidence in the near term?
Could these compliance issues trigger additional regulatory scrutiny at Alkem's other manufacturing facilities?
16
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
